UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 279

Sortiert nach

Dietary Fructose and the Metabolic Syndrome

Nutrients, 2019-08, Vol.11 (9), p.1987

2019

Link zum Volltext

Verfügbarkeit prüfen

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease

Current atherosclerosis reports, 2022-03, Vol.24 (3), p.133-142

Packard, Chris J.

2022

Link zum Volltext

Verfügbarkeit prüfen

In Memoriam: Professor James Shepherd FRSE

Atherosclerosis, 2022-08, Vol.354, p.53-54

Packard, Chris J.

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study

Circulation (New York, N.Y.), 2016-03, Vol.133 (11), p.1073-1080

2016

Link zum Volltext

Verfügbarkeit prüfen

High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease

Journal of the American College of Cardiology, 2016-12, Vol.68 (25), p.2719-2728

2016

Link zum Volltext

Verfügbarkeit prüfen

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

Nature reviews cardiology, 2022-09, Vol.19 (9), p.577-592

2022

Link zum Volltext

Verfügbarkeit prüfen

Triglyceride lowering 2.0: back to the future?

European heart journal, 2020-01, Vol.41 (1), p.95-98

Packard, Chris J

2020

Link zum Volltext

Verfügbarkeit prüfen

Keeping remnants in perspective

European heart journal, 2021-11, Vol.42 (42), p.4333-4335

2021

Link zum Volltext

Verfügbarkeit prüfen

Letter by Packard Regarding Article, “Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial”

Circulation (New York, N.Y.), 2020-11, Vol.142 (20), p.e333-e334

Packard, Chris J

2020

Link zum Volltext

Verfügbarkeit prüfen

Causes and Consequences of Hypertriglyceridemia

Frontiers in endocrinology (Lausanne), 2020-05, Vol.11, p.252-252

2020

Link zum Volltext

Verfügbarkeit prüfen

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

European heart journal, 2018-07, Vol.39 (27), p.2546-2550

2018

Link zum Volltext

Verfügbarkeit prüfen

LDL cholesterol: How low to go?

Trends in cardiovascular medicine, 2018-07, Vol.28 (5), p.348-354

Packard, Chris J.

2018

Link zum Volltext

Verfügbarkeit prüfen

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

Frontiers in endocrinology (Lausanne), 2020-07, Vol.11, p.474-474

2020

Link zum Volltext

Verfügbarkeit prüfen

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD

Current atherosclerosis reports, 2019-08, Vol.21 (8), p.27-27, Article 27

2019

Link zum Volltext

Verfügbarkeit prüfen

Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism

Circulation (New York, N.Y.), 2017-01, Vol.135 (4), p.363-365

Packard, Chris J

2017

Link zum Volltext

Verfügbarkeit prüfen

Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA: JACC State-of-the-Art Review

Journal of the American College of Cardiology, 2020-08, Vol.76 (5), p.563-579

2020

Link zum Volltext

Verfügbarkeit prüfen

Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the Horizon

Journal of the American College of Cardiology, 2023-04, Vol.81 (16), p.1565

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease

JAMA : the journal of the American Medical Association, 2019-01, Vol.321 (4), p.364

2019

Link zum Volltext

Verfügbarkeit prüfen

Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study

The Lancet (British edition), 2007-01, Vol.369 (9556), p.107-114

2007

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis

Annals of the rheumatic diseases, 2017-11, Vol.76 (11), p.1949

2017

Link zum Volltext

Verfügbarkeit prüfen

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study

European heart journal, 2023-10, Vol.44 (39), p.4186-4195

2023

Link zum Volltext

Verfügbarkeit prüfen

Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias

Current cardiology reports, 2018-08, Vol.20 (8), p.60-60, Article 60

Packard, Chris J.

2018

Link zum Volltext

Verfügbarkeit prüfen

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up

Circulation (New York, N.Y.), 2017-11, Vol.136 (20), p.1878-1891

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 279

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(245)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(279)
Japanisch
(54)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Dietary Fructose and the Metabolic Syndrome

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease

In Memoriam: Professor James Shepherd FRSE

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study

High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

Triglyceride lowering 2.0: back to the future?

Keeping remnants in perspective

Letter by Packard Regarding Article, “Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial”

Causes and Consequences of Hypertriglyceridemia

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

LDL cholesterol: How low to go?

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD

Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism

Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA: JACC State-of-the-Art Review

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the Horizon

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease

Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study

Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study

Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias

Suchergebnisse filtern